CSL Ltd Annual Report 2021

35+ Countries of operations around theworld US$10.3 billion in annual revenue 25,000+ employees around the world 1,700 R&D employees 300+ Plasma collection centres across China, Europe and North America US$4.1 billion in R&D investments in the last 5 years to advance product pipeline Our businesses CSL Behring CSL Behring is a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases. Our treatments offer promise for people who are living with conditions in the immunology, haematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. CSL Behring drives more than 80% of overall company revenue with markets in more than 100 countries across Asia Pacific, Europe, Latin America and North America. Seqirus As a leading influenza vaccine provider in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. Seqirus operates state-of-the-art production facilities in the United States (US), the United Kingdom (UK) and Australia and utilises both egg-based and cell-based manufacturing technologies as well as a proprietary adjuvant. It has leading research and development (R&D) capabilities, a broad and differentiated product portfolio and commercial operations in more than 20 countries. CSL is a global biotechnology leader that develops and delivers innovative medicines that save lives, protects public health and helps people with life-threatening medical conditions live full lives. CSL at a glance CSL Limited Annual Report 2020/21 8 3 Our Company